Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Nanobiotix S.A.

NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX to Present at the Jefferies London Healthcare Conference
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Provides Business Update and Reports Financial Results for the First Half of 2021
From NANOBIOTIX S.A.
Via Business Wire
Tickers NBTX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.